Hillrom More than Doubles Critical Care Product Production

By PR Newswire | 03.25.20

Includes ventilators, hospital beds, and vitals monitoring devices to support COVID-19 response.

Hillrom announced actions it is taking to support customers and caregivers with critical care products necessary to meet COVID-19 patient needs.
 
Hillrom's business operations continue with no material interruption as global demand for several critical products has grown substantially. The company is working to significantly ramp up production of these products, with the goal of more than doubling capacity in the following areas:
 
  • Respiratory health, especially Life2000, a non-invasive ventilator currently approved in the U.S. that is portable, lightweight and ideal for treating patients with mild to moderate respiratory distress across various acute care settings, including the emergency department, med-surg and post-ventilator weaning support. Expanded use of non-invasive ventilation can free up capacity for invasive ventilators for the most serious COVID-19 patients. Hillrom is working to increase its production capacity of Life2000 five-fold on an annualized basis.
  • ICU and med-surg unit smart beds, including the company's Progressa ICU bed, Centrella Smart+ bed, and, for international markets, the Hillrom 900 and Hillrom 900 Accella.
  • Patient monitoring and diagnostics, including the company's Connex and Spot Vital Signs monitors as well as physical assessment tools and consumables, including thermometry, probe covers and blood pressure devices and cuffs.
 
"We are committed to scaling production as rapidly as we can to meet the challenges the world is facing with COVID-19," said Hillrom president and CEO John Groetelaars. "Hillrom's critical care, vitals monitoring and respiratory products can help caregivers and patients as coronavirus continues to cause severe illness around the world. We are focused on our employees' health and safety, and on ensuring that our products are available when and where our customers and patients need them."
 
Hillrom relies on a global supply chain and has a balanced global manufacturing footprint, with manufacturing facilities located in the U.S., Europe, Asia and Mexico. The company has seen no material disruption in its supply chain to date. Hillrom's suppliers are a critical component of successfully meeting customer demand, and the company is working with its supply chain partners to minimize any potential disruption.
 
Given the fluidity of the coronavirus pandemic, Hillrom will continue to monitor and assess business operations, and will provide additional information as appropriate.